Other equities analysts have also issued reports about the company. Guggenheim boosted their price target on Merus from $44.00 to $46.00 and gave the company a buy rating in a research note on Monday, July 18th. Citigroup dropped their price target on Merus from $38.00 to $37.00 and set a buy rating on the stock in a research note on Thursday, May 19th. HC Wainwright reissued a buy rating on shares of Merus in a research note on Tuesday, May 10th. Finally, Stifel Nicolaus started coverage on Merus in a research note on Tuesday. They issued a buy rating and a $38.00 price target on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $41.56.
Merus Price Performance
Shares of MRUS stock opened at $28.93 on Wednesday. The business’s 50 day simple moving average is $23.00 and its 200 day simple moving average is $23.68. Merus has a one year low of $13.47 and a one year high of $33.09. The stock has a market capitalization of $1.26 billion, a PE ratio of -15.47 and a beta of 0.89.
Insider Activity at Merus
In related news, CEO Sven Ante Lundberg purchased 4,340 shares of the stock in a transaction that occurred on Tuesday, July 12th. The stock was acquired at an average cost of $22.97 per share, with a total value of $99,689.80. Following the transaction, the chief executive officer now owns 19,340 shares of the company’s stock, valued at approximately $444,239.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.90% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Commodore Capital LP grew its stake in Merus by 108.7% in the 4th quarter. Commodore Capital LP now owns 1,498,890 shares of the biotechnology company’s stock valued at $47,665,000 after purchasing an additional 780,754 shares during the period. Lynx1 Capital Management LP bought a new position in Merus in the 4th quarter valued at $24,912,000. Millennium Management LLC grew its stake in Merus by 39.2% in the 4th quarter. Millennium Management LLC now owns 774,767 shares of the biotechnology company’s stock valued at $24,638,000 after purchasing an additional 218,244 shares during the period. Frazier Life Sciences Management L.P. bought a new position in Merus in the 1st quarter valued at $16,630,000. Finally, Citadel Advisors LLC grew its stake in shares of Merus by 235.2% during the 4th quarter. Citadel Advisors LLC now owns 597,342 shares of the biotechnology company’s stock worth $18,995,000 after acquiring an additional 419,152 shares during the period. Institutional investors own 85.32% of the company’s stock.
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
- Get a free copy of the StockNews.com research report on Merus (MRUS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.